Sarah Stoiber

Sarah Stoiber is a partner in Goodwin’s Technology and Life Sciences group and a member of the firm’s Strategic Technology Transactions and Licensing practice. She joined Goodwin in 2016 and represents public and private companies in all stages of maturity in the technology and life sciences industries in a variety of matters, including formation, venture financings, strategic alliances, licensing transactions, M&A, initial public offerings, and other capital markets transactions. She also advises companies in their ongoing corporate matters, including corporate governance, contract negotiations, and SEC compliance.

While attending law school, Sarah served as Managing Editor of the Boston College Law Review.

Strategic Alliances and M&A:

• Kymera Therapeutics in its strategic collaboration with Vertex to advance small molecule protein degraders against multiple biological targets, with an upfront payment of $70 million to Kymera, including an equity investment, and potential future payments to Kymera in excess of $1 billion.
• Scholar Rock in its strategic collaboration with Gilead Sciences, with potential deal value of over $1.5 billion.
• ImmuNext in its global licensing and research collaboration in immunology with a major pharmaceutical company, with an upfront payment of $40 million, and potential future payments to ImmuNext in excess of $565 million.
• Fresenius Medical Care in its global partnership with Humacyte to commercialize the investigational human acellular vessel HUMACYL.
• Moderna Therapeutics in its strategic collaboration with a major pharmaceutical company to advance novel mRNA-based personalized cancer vaccines, with an upfront payment of $200 million, and the expansion of the strategic alliance to include additional shared antigen mRNA cancer vaccines, with an equity investment of $125 million.
• Teva Pharmaceuticals in its sale of its specialty global women’s health business for a combined value of $2.5 billion.
• Nimbus Therapeutics in its strategic alliance with Celgene Corporation in immunology.
• Royalty Pharma in its $827 million acquisition of Ligand Pharmaceuticals’ royalties on sales of Promacta, and its purchase of future worldwide royalties on sales of Tazemetostat by Epizyme, Inc. and Eisai Co., Ltd.
• Karyopharm Therapeutics in its $150 million royalty-based funding agreement with HealthCare Royalty Partners.
• Esperion Therapeutics in its $200 million royalty-based funding agreement with an investor group led by Oberland Capital.
• Licensing of intellectual property assets from research institutions.

Public Offerings and Public Company Representation:

• Moderna Therapeutics in its $604 million initial public offering.
• CRISPR Therapeutics in its $200 million and $120 million follow-on offerings.
• Underwriters in a $610 million initial public offering by Switch, Inc.

Venture/Mezzanine Financings:

• eGenesis, Inc. in its $100 million Series B preferred stock financing.
• Arrakis Therapeutics in its $75 million Series B preferred stock financing.
• Moderna Therapeutics in its $500 million Series G preferred stock financing.
• Nimbus Therapeutics in its $65 million Series 2018 preferred stock financing.

Sarah is a member of the Boston Bar Association.